Entrada Therapeutics, Inc (TRDA) - Koefisien utang jangka dawa marang modal

Entrada Therapeutics, Inc - logo grafis emiten TRDA

A management team with an impeccable reputation is successfully validating its technology, leveraging liquid reserves and ally support. Entrada Therapeutics (TRDA) is renowned for its cutting-edge drug delivery methods into cells for the therapy of metabolic pathologies. This price chart, which assists in the basic asset valuation, captures the 0.18 indicator. The business capitalization is based on the development of treatments for orphan diseases, while future commercial contracts will drive profitability.

Entrada Therapeutics Inc. (TRDA): Utang jangka dawa marang ekuitas saka 04.07.2022 nganti 30.10.2026
Produk mawa merek Entrada Therapeutics

This indicator compares liabilities with a maturity of over one year against net assets to determine the extent of the company's reliance on external debt financing. Optimizing this long-term debt-to-equity ratio is critical for Entrada Therapeutics (TRDA), as the deployment of automated robotic laboratories requires significant capital expenditures, which is directly reflected in the price action on this chart.